Ability to drive, benzodiazepines
The sedative effect affects the ability to drive or use machines
Agomelatine [1], benzodiazepines ---> SmPC of [1] of EMA
No evidence of pharmacokinetic or pharmacodynamic interaction was found in phase I clinical trials
Alcohol, benzodiazepines
The co-administration may cause a mutual potentiation of the depressor effect on the CNS. Alcohol consumption should be avoided
Alfentanyl [1], benzodiazepines ---> SmPC of [1] of eMC
CNS depressants may enhance or prolong the respiratory depressant effects of alfentanil.
Alizapride, benzodiazepines
The co-administration may cause a mutual potentiation of the depressor effect on the CNS
Amantadine, benzodiazepines
The co-administration is only possible by simultaneous stabilization of the blood pressure
Aminophylline, benzodiazepines
Administration of aminophylline may reduce the sedative effects of benzodiazepines
Amisulpride [1], benzodiazepines ---> SmPC of [1] of eMC
Caution is advised when coadministering amisulpride with CNS depressants
Amitriptyline, benzodiazepines
Amitriptyline may enhance the effects of CNS depressants
Anaesthetics, benzodiazepines
Enhancement of the central depressive effect may occur if benzodiazepines are combined with centrally-acting drugs
Analgesics, benzodiazepines
Enhancement of the central depressive effect may occur
Antidepressants, benzodiazepines
Enhancement of the central depressive effect may occur if benzodiazepines are combined with centrally-acting drugs
Antiepileptics, benzodiazepines
Enhancement of the central depressive effect may occur if benzodiazepines are combined with centrally-acting drugs
Antihypertensives, benzodiazepines
Enhanced hypotensive effects may occur when benzodiazepines is given to patients treated with antihypertensive agents.
Anxiolytics, benzodiazepines
Enhancement of the central depressive effect may occur if benzodiazepines are combined with centrally-acting drugs
Apraclonidine [1], benzodiazepines ---> SmPC of [1] of eMC
The possibility of an additive or potentiating effect with CNS depressants should be considered.
Azelastine, benzodiazepines
Azelastine may enhance sedation effects of other medicinal products as tranquilizers, hypnotics and alcohol
Baclofen [1], benzodiazepines ---> SmPC of [1] of eMC
The concomitant administration of baclofen and other medications that have a suppressing effect on functions of the central nervous system can enhance the action of baclofen
Barbiturates, benzodiazepines
Enhancement of the central depressive effect may occur if benzodiazepines are combined with centrally-acting drugs
Benzodiazepine analogues, breast-feeding
The benzodiazepine analog passes into the breast milk. Contraindicated
Benzodiazepine analogues, enzyme inhibitors
The enzymatic inhibition may enhance the benzodiazepine analog activity
Benzodiazepine analogues, flumazenil [2] ---> SmPC of [2] of eMC
Flumazenil antagonizes the central effects of benzodiazepine analog by competitive interaction at the receptor
Benzodiazepine analogues, melatonin [2] ---> SmPC of [2] of EMA
Melatonin may enhance the sedative properties of benzodiazepines and non-benzodiazepine hypnotics
Benzodiazepine primarily metabolised by CYP3A4, clarithromycin [2] ---> SmPC of [2] of eMC
When midazolam was co-administered with clarithromycin tablets, midazolam AUC was increased 2.7-fold after IV administration of midazolam and 7-fold after oral administration. Co-administration of oral midazolam and clarithromycin should be avoided.
Benzodiazepine primarily metabolised by CYP3A4, diltiazem [2] ---> SmPC of [2] of eMC
Special care should be taken when prescribing short-acting benzodiazepines metabolized by the CYP3A4 pathway in patients using diltiazem.
Benzodiazepine primarily metabolised by CYP3A4, fosaprepitant [2] ---> SmPC of [2] of EMA
The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolised via CYP3A4 should be considered when co-administering these medicinal products with fosaprepitant.
Benzodiazepine primarily metabolised by CYP3A4, netupitant/palonosetron [2] ---> SmPC of [2] of EMA
The potential effects of increased plasma concentrations of benzodiazepines metabolized via CYP3A4 should be considered when coadministering these active substances with netupitant/palonosetron.
Benzodiazepine primarily metabolised by CYP3A4, posaconazole [2] ---> SmPC of [2] of EMA
Concomitant use of posaconazole with any benzodiazepine that is metabolised by CYP3A4 increases plasma concentrations of the benzodiazepine. Due to the risk of prolonged sedation it is recommended that dose adjustments should be considered
Benzodiazepine primarily metabolised by CYP3A4, voriconazole [2] ---> SmPC of [2] of EMA
Voriconazole is likely to increase the plasma concentrations of benzodiazepines that are metabolised by CYP3A4 and lead to a prolonged sedative effect.
Benzodiazepines, breast-feeding ---> SmPC of [bromazepam] of eMC
Since benzodiazepines are found in the breast milk, benzodiazepines should not be given to breast feeding mothers.
Benzodiazepines, bromelain
Bromelain may increase drowsiness caused by some medicinal products
Benzodiazepines, bromperidol
Bromperidol may enhance the sedation caused by other drugs up to respiratory depression
Benzodiazepines, buprenorphine [2] ---> SmPC of [2] of EMA
This combination may result in death due to respiratory depression of central origin.
Benzodiazepines, buprenorphine/naloxone [2] ---> SmPC of [2] of EMA
This combination may result in death due to respiratory depression of central origin.
Benzodiazepines, buspirone [2] ---> SmPC of [2] of eMC
The concomitant use of buspirone with other CNS-active drugs should be approached with caution.
Benzodiazepines, caffeine
Caffeine may decrease the effect of benzodiazepines
Benzodiazepines, carisoprodol
The co-administration may enhance the depressive effect on the central nervous system.
Benzodiazepines, cenobamate [2] ---> SmPC of [2] of EMA
Concomitant use of cenobamate with other CNS depressants, including alcohol, barbiturates, and benzodiazepines may increase the risk of neurological adverse reactions.
Benzodiazepines, certoparin
Displacement of benzodiazepine from its plasma protein binding
Benzodiazepines, chlomethiazole
Possible mutual potentiation of effects
Benzodiazepines, chlorpromazine [2] ---> SmPC of [2] of eMC
The co-administration may increase the CNS depressant effect
Benzodiazepines, cimetidine [2] ---> SmPC of [2] of eMC
Known inhibitors of hepatic enzymes, e.g. cimetidine, have been shown to reduce the clearance of benzodiazepines and may potentiate their action
Benzodiazepines, clomipramine [2] ---> SmPC of [2] of eMC
Tricyclic antidepressants may potentiate the effects of other central depressant substances
Benzodiazepines, cloperastine
Increased CNS depressant effect
Benzodiazepines, clozapine [2] ---> SmPC of [2] of eMC
Particular caution is advised when clozapine therapy is initiated in patients who are receiving a benzodiazepine or any other psychotropic agent. These patients may have an increased risk of circulatory collapse
Benzodiazepines, CNS depressants
Enhancement of the central depressive effect may occur if benzodiazepines are combined with centrally-acting drugs
Benzodiazepines, cyclophosphamide
The previous or concomitant treatment of benzodiazepines may increase the metabolism and thus enhance the effect of cyclophosphamide due to increasing formation of active alkylating metabolites of cyclophosphamide
Benzodiazepines, dalteparin
Dalteparin may displace the benzodiazepine from its protein binding.
Benzodiazepines, dantrolene
The co-administration of dantrolene and CNS depressants should be avoided due to the adverse reactions of dantrolene may be enhanced (specially the CNS depressant effect and muscle weakness)
Benzodiazepines, desflurane
Patients receiving benzodiazepines showed a marked reduction in the anaesthetic requirements or MAC.
Benzodiazepines, dexchlorpheniramine
The combination of dexchlorpheniramine with other CNS depressants may enhance the CNS depressant effect
Benzodiazepines, diazoxide
The co-administration of diazoxide and benzodiazepines may potentiate the effect of diazoxide
Benzodiazepines, dimenhydrinate
Dimenhydrinate may increase the effects of other CNS depressors and enhance the sedative effects
Benzodiazepines, dipotassium clorazepate
The co-administration may increase the risk of developing dependency
Benzodiazepines, droperidol [2] ---> SmPC of [2] of eMC
Droperidol may potentiate the action of sedatives
Benzodiazepines, duloxetine [2] ---> SmPC of [2] of EMA
Caution is advised when duloxetine is taken in combination with other centrally acting medicinal products or substances, including alcohol and sedative medicinal products
Benzodiazepines, elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide [2] ---> SmPC of [2] of EMA
Concentrations of other benzodiazepines, including diazepam, may be increased when administered with Genvoya. With other sedatives/hypnotics, dose reduction may be necessary and concentration monitoring is recommended.
Benzodiazepines, enoxaparin
Displacement of benzodiazepine from its plasma protein binding sites
Benzodiazepines, enzyme inductors
Inducers may increase clearance of benzodiazepines
Benzodiazepines, enzyme inhibitors
Known inhibitors of hepatic enzymes, particularly cytochrome P450 have been shown to reduce the clearance of benzodiazepines and may potentiate their action
Benzodiazepines, erythromycin [2] ---> SmPC of [2] of eMC
Inhibitors reduce clearance and may potentiate the action of benzodiazepines.
Benzodiazepines, esketamine
Concomitant use of Spravato with CNS depressants (e.g., benzodiazepines, opioids, alcohol) may increase sedation, which therefore should be closely monitored.
Benzodiazepines, esomeprazole ---> SmPC of [lorazepam] of eMC
Inhibitors reduce clearance and may potentiate the action of benzodiazepines.
Benzodiazepines, ethyl loflazepate
The co-administration may cause a mutual potentiation of the depressor effect on the CNS
Benzodiazepines, fluconazole [2] ---> SmPC of [2] of eMC
If concomitant benzodiazepine therapy is necessary in patients being treated with fluconazole, consideration should be given to decreasing the benzodiazepine dose, and the patients should be appropriately monitored.
Benzodiazepines, flumazenil [2] ---> SmPC of [2] of eMC
Flumazenil antagonizes the central effects of benzodiazepines by competitive interaction at the receptor
Benzodiazepines, granisetron [2] ---> SmPC of [2] of EMA
In studies in healthy subjects, no evidence of any interaction has been indicated between granisetron and benzodiazepines (lorazepam), neuroleptics (haloperidol) or anti-ulcer medicinal products (cimetidine).
Benzodiazepines, guanfacin [2] ---> SmPC of [2] of EMA
Caution should be used when Intuniv is administered concomitantly with CNS depressant medicinal products due to the potential for additive pharmacodynamic effects such as sedation and somnolence.
Benzodiazepines, halogenated anaesthetics
Benzodiazepines are expected to decrease the MAC of inhalational anaesthetics.
Benzodiazepines, heparin ---> SmPC of [sodium heparin] of eMC
Heparin may increase the effect of benzodiazepines
Benzodiazepines, hypnotics
Enhancement of the central depressive effect may occur if benzodiazepines are combined with centrally-acting drugs
Benzodiazepines, IMAOs
The co-administration may enhance the depressive effect on the central nervous system (e.g. increased sedation, respiratory depression)
Benzodiazepines, imipramine [2] ---> SmPC of [2] of eMC
Tricyclic antidepressants may potentiate the CNS depressant effects of central depressant drugs
Benzodiazepines, isoflurane [2] ---> SmPC of [2] of eMC
Opioids, benzodiazepines and other sedative agents are associated with respiratory depression, and caution should be exercised when concomitantly administered with isoflurane.
Benzodiazepines, isoniazid ---> SmPC of [lorazepam] of eMC
Inhibitors reduce clearance and may potentiate the action of benzodiazepines.
Benzodiazepines, ketamine
The co-administration may prolong the ketamine duration of effect and weaken the adverse effects
Benzodiazepines, levodopa
Concurrent use of levodopa with benzodiazepines may decrease the therapeutic effects of levodopa
Benzodiazepines, levodopa/carbidopa [2] ---> SmPC of [2] of EMA
Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone), benzodiazepines and isoniazid may reduce the therapeutic effects of levodopa.
Benzodiazepines, levomethadone
Enhancement of effects and adverse effects, particularly respiratory depression
Benzodiazepines, lidocaine
Concomitant use of lidocaine and CNS depressants may cause additive depressor effect. Special caution is recommended
Benzodiazepines, loprazolam [2] ---> SmPC of [2] of eMC
The risk of a withdrawal syndrome occurring is increased when loprazolam is combined with other benzodiazepines prescribed as anxiolytics or hypnotics.
Benzodiazepines, loxapine [2] ---> SmPC of [2] of EMA
The co-administration may be associated with excessive sedation and respiratory depression or respiratory failure.
Benzodiazepines, magaldrate
Decreased absorption of benzodiazepine. It is recommended to administer the two substances at least 2-3 hours apart.
Benzodiazepines, maprotiline
Maprotiline may enhance the effects of CNS depressant
Benzodiazepines, melatonin [2] ---> SmPC of [2] of EMA
Melatonin may enhance the sedative properties of benzodiazepines and non-benzodiazepine hypnotics
Benzodiazepines, mequitazine
Central nervous system depressants may enhance the sedative effects of mequitazine
Benzodiazepines, methadone [2] ---> SmPC of [2] of eMC
The depressant effects of methadone are likely to be enhanced by depressants of the CNS. As well as CNS depression, there may be respiratory depression and/or hypotension.
Benzodiazepines, methocarbamol
Methocarbamol may potentiate the effects of other central nervous system depressants and stimulants
Benzodiazepines, methyldopa
Enhancement of CNS depressor effect
Benzodiazepines, midazolam [2] ---> SmPC of [2] of EMA
The co-administration of midazolam with other sedative/hypnotic agents and CNS depressants, including alcohol, is likely to result in enhanced sedation and respiratory depression.
Benzodiazepines, mirtazapine [2] ---> SmPC of [2] of eMC
Mirtazapine may potentiate the sedative effects. Caution is recommended
Benzodiazepines, moxonidine [2] ---> SmPC of [2] of eMC
Moxonidine may enhance the sedative effect of benzodiazepines when administered concomitantly.
Benzodiazepines, muscle relaxants ---> SmPC of [dipotassium clorazepate] of eMC
The co-administration may have an additive muscle relaxant effect
Benzodiazepines, nadroparin
Displacement of nadroparin from its plasma protein binding
Benzodiazepines, nalbuphine
Other central nervous system depressant drugs may increase the risk of respiratory depression, which can be life-threatening in the case of an overdose
Benzodiazepines, narcotics
The co-administration may cause a mutual potentiation of the depressor effect on the CNS and enhance the euphoric effect and the psychic dependence
Benzodiazepines, neuroleptics
Enhancement of the central depressive effect may occur if benzodiazepines are combined with centrally-acting drugs
Benzodiazepines, nitrous oxide
Additive effect on the CNS. It should be taken into account the pronounced sedative risk and depression of the protective reflexes
Benzodiazepines, omeprazole ---> SmPC of [lorazepam] of eMC
Inhibitors reduce clearance and may potentiate the action of benzodiazepines.
Benzodiazepines, opioid analgesics
Enhancement of the central depressive effect may occur if benzodiazepines are combined with centrally-acting drugs. Enhancement of the euphoria may also occur leading to an increase in psychological dependence.
Benzodiazepines, opipramol
The co-administration may enhance the depressive effect on the central nervous system (e.g. increased sedation, respiratory depression)
Benzodiazepines, oxomemazine
Enhancement of CNS depressant effect
Benzodiazepines, pethidine [2] ---> SmPC of [2] of eMC
The central depressant effects of pethidine may be potentiated by the concurrent use of other CNS depressants; respiratory depression and profound sedation or coma may occur.
Benzodiazepines, phenobarbital [2] ---> SmPC of [2] of eMC
Concurrent administration of phenobarbital with other CNS depressants may lead to an additive CNS depressant effects
Benzodiazepines, phenothiazines
Phenothiazine may enhance the effect of other CNS depressants
Benzodiazepines, phenytoin [2] ---> SmPC of [2] of eMC
Benzodiazepines may increase phenytoin serum levels
Benzodiazepines, pipamperone
Potentiation of the depressor effect on the CNS
Benzodiazepines, piritramide
The co-administration may enhance the adverse effects of piritramide, particularly respiratory depression
Benzodiazepines, primidone
Primidone, enzymatic inductor, may accelerate the metabolism of benzodiazepine and decrease its plasma levels and effect
Benzodiazepines, probenecide
Probenecid increases the exposure to benzodiazepine
Benzodiazepines, promethazine
The co-administration of promethazine and other central nervous depressants can mutually enhance the effects and adverse reactions (particularly sedation and hypotension)
Benzodiazepines, propiverine [2] ---> SmPC of [2] of eMC
Increased effects of propiverine due to concomitant medication with tranquillisers (e.g. benzodiazepines)
Benzodiazepines, propofol
The co-administration may prolong the anesthesia duration and decrease the respiratory rate
Benzodiazepines, proteolytic enzymes enriched in bromelain [2] ---> SmPC of [2] of EMA
Bromelain may increase drowsiness caused by some medicinal products
Benzodiazepines, remifentanil [2] ---> SmPC of [2] of eMC
As with other opioids remifentanil decreases the amounts or doses of benzodiazepines required for anaesthesia
Benzodiazepines, rifampicin [2] ---> SmPC of [2] of eMC
Rifampicin is a potent inducer of certain cytochrome P-450 enzymes. Coadministration of rifampicin with drugs that are also metabolised through these cytochrome P-450 enzymes may accelerate the metabolism and reduce the activity of these other drugs.
Benzodiazepines, risperidone [2] ---> SmPC of [2] of eMC
Risperidone should be used with caution in combination with benzodiazepins due to the increased risk of sedation
Benzodiazepines, ritonavir [2] ---> SmPC of [2] of eMC
Ritonavir may inhibit benzodiazepine hepatic metabolism
Benzodiazepines, rotigotine [2] ---> SmPC of [2] of EMA
Because of possible additive effects, caution should be advised when patients are taking sedating medicinal products or other CNS (central nervous system) depressants or alcohol in combination with rotigotine.
Benzodiazepines, sedating antihistamines
Enhancement of the central depressive effect may occur if benzodiazepines are combined with centrally-acting drugs
Benzodiazepines, sedatives
Enhancement of the central depressive effect may occur
Benzodiazepines, sevoflurane [2] ---> SmPC of [2] of eMC
Benzodiazepines are expected to decrease the MAC of sevoflurane in the same manner as with other inhalational anaesthetics.
Benzodiazepines, sodium heparin
Heparin may increase the effect of benzodiazepines
Benzodiazepines, sodium iodide
The withdrawal period prior to administration of sodium [131I]iodine is ca. 4 weeks
Benzodiazepines, sodium oxybate [2] ---> SmPC of [2] of EMA
Given the possibility of increasing the risk of respiratory depression, the concomitant use of benzodiazepines and sodium oxybate should be avoided.
Benzodiazepines, sodium valproate [2] ---> SmPC of [2] of eMC
Valproate may potentiate the effect of other psychotropics; therefore, clinical monitoring is advised and the dosage of the other psychotropics should be adjusted when appropriate.
Benzodiazepines, sufentanil [2] ---> SmPC of [2] of EMA
The concomitant use of CNS depressants including barbiturates, benzodiazepines, neuroleptics or other opioids, halogen gases or other non-selective CNS depressants (e.g. alcohol) may enhance respiratory depression.
Benzodiazepines, sulpiride
Sulpiride enhances the sedative effect of benzodiazepine
Benzodiazepines, tapentadol [2] ---> SmPC of [2] of eMC
The co-administration may increase the risk of respiratory depression and enhance the sedative effect of tapentadol
Benzodiazepines, tetracyclic antidepressant
Enhancement of the central depressive effect may occur if benzodiazepines are combined with centrally-acting drugs
Benzodiazepines, tetrazepam
Tetrazepam should not be administrated with other benzodiazepines due to the risk of further increase of dependence development and abstinence symptoms
Benzodiazepines, theophylline [2] ---> SmPC of [2] of eMC
There is a pharmacological interaction with benzodiazepines and these drugs should be used with caution.
Benzodiazepines, thiethylperazine
The co-administration may potentiate the CNS depressant effect
Benzodiazepines, thiopental
The CNS depressant can enhance the respiratory depressor effect of thiopental
Benzodiazepines, thioridazine
Phenothiazine may enhance the effect of other CNS depressants
Benzodiazepines, tiapride
Enhancement of CNS depressant effect
Benzodiazepines, tizanidine [2] ---> SmPC of [2] of eMC
Sedatives may enhance the sedative action of tizanidine.
Benzodiazepines, tocilizumab [2] ---> SmPC of [2] of EMA
When starting or stopping therapy with tocilizumab, patients taking medicinal products which are individually adjusted and are metabolised via CYP450 3A4, 1A2 or 2C9 should be monitored as doses may need to be increased to maintain therapeutic effect.
Benzodiazepines, tramadol [2] ---> SmPC of [2] of eMC
Concomitant administration of tramadol with other centrally acting drugs may potentiate CNS depressant effects.
Benzodiazepines, tranquilizers
Enhancement of the central depressive effect may occur if benzodiazepines are combined with centrally-acting drugs
Benzodiazepines, tranylcypromine
The effect of CNS depressants can be enhanced by co-administration of tranylcypromine
Benzodiazepines, tricyclic antidepressant [2] ---> SmPC of [2] of eMC
Enhancement of the central depressive effect may occur if benzodiazepines are combined with centrally-acting drugs
Benzodiazepines, tryptophan
The co-administration may cause sexual disinhibition, reversible dyskinesia and parkinsonian symptoms
Benzodiazepines, valproic acid [2] ---> SmPC of [2] of eMC
Valproate may potentiate the effect of other psychotropics; therefore, clinical monitoring is advised and the dosage of the other psychotropics should be adjusted when appropriate.
Benzodiazepines, venlafaxine [2] ---> SmPC of [2] of eMC
Venlafaxine has no effects on the pharmacokinetics and pharmacodynamics of diazepam and its active metabolite, desmethyldiazepam. It is unknown whether a pharmacokinetic and/or pharmacodynamic interaction with other benzodiazepines exists.
Benzodiazepines, xanthines
Xanthines accelerate the metabolism and reduce the sedative and anxiolytic effects of benzodiazepines.
Benzodiazepines, zidovudine ---> SmPC of [oxazepam] of eMC
Concurrent use of zidovudine with benzodiazepines may decrease zidovudine clearance.
Boceprevir [1], intravenous benzodiazepines ---> SmPC of [1] of EMA
Close clinical monitoring for respiratory depression and/or prolonged sedation should be exercised during co-administration of Victrelis with intravenous benzodiazepines. Dose adjustment of the benzodiazepine should be considered.
Imatinib [1], triazolobenzodiazepines ---> SmPC of [1] of EMA
Glivec may increase plasma concentration of other CYP3A4 metabolised drugs (e.g. triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, i.e. statins, etc.).